Replies to Post #242268 onBiotech Values | InvestorsHub

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

News Focus

News Focus

Replies to post #242268 on Biotech Values

Replies to #242268 on Biotech Values

04/29/22 8:18 AM

#242270 RE: DewDiligence #242268

BMY addendum—Eliquis sold at $13B(!) annualized rate in 1Q22.

07/27/22 7:46 AM

#243306 RE: DewDiligence #242268

BMY 2Q22 results:

https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2022/default.aspx

2022 non-GAAP EPS guidance remains $7.44-7.74.